Cantisán Sara, Torre-Cisneros Julián, Lara Rosario, Rodríguez-Benot Alberto, Santos Francisco, Gutiérrez-Aroca Juan, Gayoso Inmaculada, González-Padilla Marcelino, Casal Manuel, Rivero Antonio, Solana Rafael
Instituto Maimónides para la Investigación Biomédica de Córdoba, Córdoba 14004, Spain.
Clin Vaccine Immunol. 2009 Oct;16(10):1429-38. doi: 10.1128/CVI.00214-09. Epub 2009 Aug 5.
In this cross-sectional study of 42 solid organ transplant recipients, the association of human cytomegalovirus (HCMV) replication and age with the phenotype of the HCMV-specific CD8(+) T cells was analyzed by using the CMV pp65 HLA-A*0201 pentamer. A correlation between the proportion of CD28(-) HCMV-specific CD8(+) T cells and age was observed in patients without HCMV replication (r = 0.50; P = 0.02) but not in patients with HCMV replication (r = -0.05; P = 0.83), a finding which differs from that observed for total CD8(+) T cells. Within the group of patients younger than 50 years of age, patients with HCVM replication after transplantation had higher percentages of CD28(-) HCMV-specific CD8(+) T cells (85.6 compared with 58.7% for patients without HCMV replication; P = 0.004) and CD27(-) HCMV-specific CD8(+) T cells (90.7 compared with 68.8% for patients without HCMV replication; P = 0.03). However, in patients older than age 50 years, a high frequency of these two subpopulations was observed in patients both with and without previous HCMV replication (for CD28(-) HCMV-specific CD8(+) T cells, 84.4 and 80.9%, respectively [P = 0.39]; for CD27(-) HCMV-specific CD8(+) T cells 86.6 and 81.5%, respectively [P = 0.16]). In conclusion, the present study shows that in the group of recipients younger than age 50 years, HCMV replication after transplantation is associated with a high percentage of CD27(-) and CD28(-) HCMV-specific CD8(+) T cells. These results suggest that the increased percentage of CD27(-) or CD28(-) HCMV-specific subsets can be considered a biomarker of HCMV replication in solid organ transplant recipients younger than age 50 years but not in older patients. Further studies are necessary to define the significance of these changes in HCMV-associated clinical complications posttransplantation.
在这项针对42名实体器官移植受者的横断面研究中，通过使用巨细胞病毒（CMV）pp65 HLA-A*0201五聚体，分析了人类巨细胞病毒（HCMV）复制及年龄与HCMV特异性CD8(+) T细胞表型之间的关联。在无HCMV复制的患者中观察到CD28(-) HCMV特异性CD8(+) T细胞比例与年龄之间存在相关性（r = 0.50；P = 0.02），但在有HCMV复制的患者中未观察到这种相关性（r = -0.05；P = 0.83），这一发现与总CD8(+) T细胞的情况不同。在年龄小于50岁的患者组中，移植后有HCMV复制的患者中，CD28(-) HCMV特异性CD8(+) T细胞的百分比更高（分别为85.6%和58.7%，无HCMV复制的患者；P = 0.004），CD27(-) HCMV特异性CD8(+) T细胞的百分比也更高（分别为90.7%和68.8%，无HCMV复制的患者；P = 0.03）。然而，在年龄大于50岁的患者中，无论之前有无HCMV复制，这两个亚群的频率都较高（对于CD28(-) HCMV特异性CD8(+) T细胞，分别为84.4%和80.9% [P = 0.39]；对于CD27(-) HCMV特异性CD8(+) T细胞，分别为86.6%和81.5% [P = 0.16]）。总之，本研究表明，在年龄小于50岁的受者组中，移植后HCMV复制与高比例的CD27(-)和CD28(-) HCMV特异性CD8(+) T细胞相关。这些结果表明，CD27(-)或CD28(-) HCMV特异性亚群百分比的增加可被视为年龄小于50岁的实体器官移植受者中HCMV复制的生物标志物，但在老年患者中并非如此。有必要进一步研究以确定这些变化在移植后HCMV相关临床并发症中的意义。
